Halozyme Wins Dutch Patent Infringement Case Against Merck's Keytruda SC
A Dutch court ruled in favor of Halozyme Therapeutics, finding that Merck infringed on its EP622 MDASE patent related to subcutaneous drug delivery technology. The ruling orders MSD BV (Merck’s European subsidiary) to stop all commercial activities involving Keytruda SC across eight European markets. The decision could impact the availability and marketing of Keytruda SC, a key immunotherapy treatment for various cancers in Europe. Merck may face delays or modifications to its product strategy if it chooses not to appeal the ruling immediately. Halozyme’s victory reinforces its IP position in subcutaneous delivery technology, which is critical for several biopharmaceutical products. This legal win could lead to licensing discussions between the two companies and potentially result in financial compensation for Halozyme.
Topics: legal action patents pharmaceuticals